Mirum Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) on September 2, 2022, regarding events occurring on September 1, 2022. The Company is a Delaware corporation headquartered in Foster City, California, and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the resignation of Edward T. Mathers. Effective September 1, 2022, Mr. Mathers stepped down from his roles as a director of the Company and as a member of the Compensation Committee. The Company explicitly stated that this resignation was not the result of any dispute or disagreement regarding the Company's operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No new risks, contingencies, or unusual items were disclosed in this specific report.
Key Facts for Investor Verification
- Edward T. Mathers resigned as a director and Compensation Committee member effective September 1, 2022.
- The resignation was voluntary and not related to any disagreement with the Company.
- Christopher Peetz, President and CEO, signed the report on behalf of the Company.
- No financial data or operational updates were included in this filing.